Precedent Decision from Ankara Court: SGK Will Cover Cancer Patient's Smart Medicine Cost!
An important legal victory was achieved for a patient receiving treatment for salivary gland cancer in Ankara. Ankara 62. Labor Court, what the patient should use “erdafitinib” Social Security Institution determines the cost of the smart drug containing the active ingredient. (Textbook) ruled to be covered by.
İ.A., who lives in Ankara, was diagnosed with salivary gland cancer a while ago.. When the expected results are not obtained from the patient's standard chemotherapy and radiotherapy treatments, It was decided to switch to smart medicine application. Gene test performed, showed that the drug in question was fully compatible with the patient's genetic structure. However, prescribed “erdafitinib” The active ingredient of this medicine, It was reported that it will not be covered by the institution since it is not included in the SSI reimbursement list..
The Court Accepted the Request for Injunction: 6 Monthly Usage from SSI
Upon the rejection decision of SSI, İ.A., He applied to the court through his lawyer Eliz Atlı and requested that the cost of the medicine be covered by SGK. interim injunction requested.
Ankara 62. Labor Court, evaluated the application and accepted the request for interim measures.. Court, The cost of this vital drug, from the date of decision 6 It will be covered by SGK free of charge and without interruption during the monthly usage period. decided. Moreover, A provision was also made that the payment required for the procurement of the drug from abroad should be made to the Turkish Pharmacists Association Overseas Drug Supply Unit without delay and the treatment should begin immediately..
Lawyer Atlı: “We Restricted the Use of the Drug as a Result of a Legal Struggle”
İ.A.'s lawyer Eliz Atlı, He explained his client's difficult treatment process:
“When our client could not get full results despite standard treatments, smart medicine application was started.. Although the first smart drug used provides benefits for a while,, The body developed resistance and the tumor spread close to the carotid artery, which worsened the situation. Thereupon, we had a gene test and found that the drug was exactly compatible with the genetic structure.. As a result of the legal struggle we initiated after SSI rejected the claim on the grounds that it was not on the reimbursement list., by taking precautionary measures We have opened the use of the drug to our client's approval..”
this decision, It has the potential to set an example for cancer patients and individuals struggling with rare diseases in similar situations..
